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Learning objectives
To focus on the role of new imaging-based criteria for monitoring targeted therapies in
malignant tumors in assessing treatment success, in identifying complications and in
decision-making for subsequent therapy.
Background
Targeted therapies are more and more often widely used for cancer treatment. These
tharapies inhibit tumor cell growth or affect tumor angiogenesis, without necessarily
causing tumor cell death; hence radiological images may vary showing, for example on
CT a reduced blood supply and tumor tissue necrosis as a reduced tumor density.
Tumor response assessment is essential to evaluate treatment success, to identify
complications, and to lead decision-making for subsequent therapy. Many imaging
techniques have been involved for evaluating tumor response to therapy, but measuring
tumor shrinkage on CT is the current standard.
Traditional imaging-based approaches to assess tumor response, such as WHO criteria,
were based on measuring tumor size [1], but, as already stated, target therapies may
cause changes in tumour attenuation and do not necessarily cause marked tumour size
reduction.
Hence, in the last decades, there has been a proliferation of many imaging-based tumor-
specific response criteria whose purpose is to achieve objective assessment of treatment
response in oncologic clinical trials[2-12].
Findings and procedure details
CT is the current standard in the measurement of tumor shrinkage, but other imaging
modalities, such as ultrasound, MRI and PET have been involved in the newly developed
response criteria to evaluate tumor response to targeted therapy.
Newly imaging based criteria include the Choi response criteria for gastrointestinal
stromal tumor, modified Response Evaluation Criteria in Solid Tumors version and
European Association for the Study of the Liver (EASL) criteria for hepatocellular
carcinoma, Immune-related Response Criteria for melanoma and Response Assessment
in Neuro-Oncology (RANO) criteria for high grade malignant glioma. PET is used
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to assess functional information and tumour viability in Cheson criteria and Positron
Emission Tomography Response Criteria in Solid Tumors (PERCIST).
RECIST (Response Evaluation Criteria in Solid Tumours) were firstly published in 2000
by a task force that comprised the European Organization for Research and Treatment
in Oncology, the National Cancer Institute of the United States, and the National Cancer
Institute of Canada, and then revised in 2009. Main tips of RECIST 1.1 which assess
response to therapy in solid tumours are reported in Table 1 [2-4].
However, due to the limits of RECIST, which are mainly based on a morphologic
assessment and to the need of having functional biological information, the so-
called PERCIST (PET-Response Criteria in Solid Tumors) have been proposed [5]. In
PERCIST, response to therapy is evaluated as a continuous variable and expressed
as a percentage change in SUL (lean body mass-normalized SUV [SUVlbm]) peak for
the most active lesion at each time point between the pre- and posttreatment PET/CT
studies. Though recent preclinical studies reported that PET imaging is useful tools for
early response monitoring of many new target therapies, due to the limited availability of
PET and to economic reasons, these criteria have not yet been further developed.
Choi criteria [6] are used to assess gastrointestinal stromal tumor response to target
therapies and evaluate both size and another quantitative parameter, tumor density (see
Videos 1 and 2). These criteria, incorporating tumor density and using small changes
in tumor size on CT, proved to be more sensitive and more precise than RECIST in
assessing the response of GISTs. The objective evaluation according to Choi Criteria
is performed based on the measurements of tumor density (HU) and size (cm): a
combination of tumor density (>15% change) and modified tumor size (>10%) proved to
have an excellent prognostic value in assessing the response to imatinib in GISTs.
The therapeutic advances led to the FDA approval in 2007 of a target therapy also
in patients with hepatocellular carcinoma (HCC), which is recognized as the most
chemo-resistant tumour types. Nowadays, sorafenib remains the only drug that has
demonstrated survival benefits in patients with advanced HCC.
According to literature, RECIST 1.1 may not be the best criteria for monitoring treatment
response in HCC. For this reason, new criteria, EASL [7] and mRECIST [8] ones have
been proposed to assess response to therapy in HCC as reported in Table 2.
Immune-related response criteria (irRC) were proposed in 2009 to evaluate response to
treatment with immunotherapy in malignant melanoma[9,10] (see Table 3).
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Patients with high grade malignant glioma treated with target therapies should be
evaluated at MR through RANO criteria [11] as shown in Table 4. However, an overall
timepoint response is obtained combining radiological features with clinical ones.
Images for this section:
Fig. 1: Video 1. Liver metastasis from GIST. Abdominal CT shows liver increased in
size, with abnormal density because of the presence in the segments V, VI and VIII of a
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voluminous oval mass (diameter: 10.8 cm x 7 cm), which displaces but does not infiltrate
the right hepatic vein. This mass inhomogeneously enhances, mainly in the peripheral
portion, and shows a constantly hypodense area inside, as in necrosis. At least other 4
similar formations are reported, respectively, in correspondence of the segments IVa ,
VII - VIII , II - III and III.
Fig. 2: Video 2. Liver metastasis from GIST after target therapy with Imatinib evaluated
according to Choi Criteria in the same patient shows that the mass in the segments V,
VI and VIII is lower in size ( 9 cm X 6 cm ) and changed in density with more colliquative
hypodense areas with more coarse calcifications inside compared to the previous control.
Moreover, it is documented an increase in size of the two already known formations with
a clear ring- enhancement as an expression of activity disease .
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Table 2: Table 2. Assessment of response to therapy from complete response to
progressive disease in advanced HCC according to mRECIST and EASL criteria.
Table 3: Table 3. Key features of irRC showing what radiologists should assess and how
to evaluate the disease after target therapies in patients with malignant melanoma.
Table 1: Table 1. Key features of RECIST 1.1 showing what radiologists should assess,
how and when to evaluate the disease after therapy with target therapies.
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Table 4: Table 4. RANO criteria to evaluate at MR high grade malignant glioma treated
with target therapies.
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Conclusion
Quantitative and qualitative imaging-based response criteria should be more widely
known and applied in clinical practice, since traditional imaging approaches may fail in
assessing response to target therapies.
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